Legend Biotech
Presence
Legend Biotech is a company listed under the stock ticker LEGN (US).
Executives
View the org chart displaying its 26 main executives
Most searched biographies at Legend Biotech
- Ying Huang, Director, Chief Executive Officer and Chief Financial ...
- Frank Zhang, Chairman of the Board
- Philip Yau, Director
Create your alert
to follow the executive moves at Legend Biotech.
Biotechnology
Legend Biotech has 2,275 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
- Nurix Therapeutics has just announced a $175 Million fundraising (posted on April 13 2024).
Popular contacts in Biotechnology
News
Press releases by Legend Biotech
- Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report – Legend BiotechBack ButtonSearch IconFilter Icon
- CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma – Legend BiotechBack ButtonSearch IconFilter Icon
- Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights – Legend BiotechBack ButtonSearch IconFilter Icon
- Newsroom - Legend Biotech
- Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy – Legend BiotechBack ButtonSearch IconFilter Icon
- Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results – Legend BiotechBack ButtonSearch IconFilter Icon
- Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel) – Legend BiotechBac
- Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference – Legend BiotechBack ButtonSearch IconFilter Icon
- Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3 – Legend BiotechBack ButtonSearch IconFilter Icon
- Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel) – Legend BiotechBac
- View more press releases Close
Social media about Legend Biotech
- Legend Biotech on Wikipedia, Google News & Yahoo Finance
- Legend Biotech on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Ying Huang 
Call Legend Biotech at +1 173 ...
